Stockreport

VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection

VBI Vaccines, Inc. - Ordinary Shares  (VBIV) 
Last vbi vaccines, inc. - ordinary shares earnings: 11/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: vbivaccines.com/investors
PDF - Novel recombinant, protein-based immuno-therapeutic for the treatment of chronic hepatitis B virus (HBV) infection- Two-part, dose-escalation study expected to enroll [Read more]